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1. Introduction 
Renal tumors account for more than 50,000 new cases annually in the United States with a 
rising incidence (Chow et al., 1999). This is mainly because of an increase in diagnosis due to 
widespread use of cross-sectional imaging (Pantuck et al., 2001). Renal cell carcinoma 
constitutes 4% of all adult malignancies (American Cancer Society, 2008) and about 70 to 80 
percent of patients presenting with localized limited-stage disease (Luciani et al., 2000; 
Janzen et al.,2003). Nephron-sparing surgery remians the gold standard treatment for small 
renal tumors. Although operative resection has been shown to be effective for treatment of 
small renal tumors and for preservation of renal function, it does have morbidity and 
mortality risks (Fergany et al., 2000; Gill et al., 2007; Breda et al., 2009). Early laparoscopic 
renal cryoablation results have shown technical feasibility and offer a less invasive 
technique for destroying small renal tumors (Spaliviero et al., 2004). Image-guided 
percutaneous ablation of small renal tumors is less invasive, incurs less damage to 
uninvolved noncancerous renal tissue and is becoming a viable alternative to nephron-
sparing surgery (Hui et al., 2008, Gontero et al., 2010).  
2. General concepts of percutaneous image-guided ablation 
Ablation refers to the destruction of tissue in its original location without the removal of the 
treated tissue. A resection refers to the removal of tissues from the body. Cross-sectional 
imaging modalities enable the operator to safely target the tumor through the skin without the 
need for incisions (percutaneous). The most common imaging guidance modalities are 
ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI). Energy is 
applied to the tumor via placement of needle-like devices called probes or applicators. The 
energy deposition results in irreversible damage to the tissues in its field; this area is called the 
ablation zone. Ablation procedures are usually performed by interventional radiologists 
and/or urologists (the operating physician). It can be performed in an outpatient setting. The 
most important factors in determining the outcome of an ablation are tumor size and location 
of tumor within the kidney. The best results are achieved in tumors less than 4 cm in diameter 
(Boss et al., 2005; Miki et al., 2006). The least challenging tumor location is posterior exophytic 
and the most challenging locations are central hilar and anterior. Central tumors carry a higher 
risk for bleeding, a higher risk of damage to hilar structures such as collecting system and 
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vessels, and have a higher recurrence rate due to thermal sink effect. The thermal sink effect 
refers to the phenomenon whereby the thermal energy deposition to a tumor during ablation 
is dissipated by the blood flow in the vessels abutting the tumor. Depending on the location of 
an anterior tumor, it may be approachable percutaneously. However, treatment of these 
tumors may require a trans-renal or trans-hepatic approach. All tumors less than 3 cm can be 
treated in one session and the need for more than one ablation session increases with tumor 
size larger than 3 cm (Boss et al., 2005). Ablation of a 5 to 10 mm margin around the tumor is 
ideal  to minimize the risk of recurrence. 
3. Ablation modalities 
The choice of percutaneous ablation modality is based on the availability of equipment, the 
operating physician’s experience with a particular device and limitations based on anatomy 
and patient body habitus.  
3.1 Radiofrequency ablation and cryoablation 
Radiofrequency ablation (RFA) and cryoablation are the two most commonly used ablation 
modalities (Gervais et al., 2000; Joniau et al., 2010; Atwell et al., 2008). RFA destroys tumors 
by denaturing and hydrolyzing tumor proteins by heating them to temperatures above 
60°C, whereas cryoablation destroys tumors by the formation of intracellular ice crystals 
which disrupt cell membranes by cooling them to temperatures generally below -20°C. 
Pathologically, both processes result in coagulation necrosis in the center and apoptosis in 
periphery of the treated tissues. , Both modalities are minimally invasive, as the thermal 
energy is applied by placing one or more probes into tumors. Each has unique technical 
features, and neither of the two has clearly been proven to be superior to the other 
(Maybody & Solomon, 2007; Mouraviev et al., 2007)(Table 1).  
 
Radiofrequency Ablation Cryoablation 
Typical ablation: 20-30 minutes Typical ablation: 30-40 minutes 
Less bleeding More bleeding 
More pain (greater need for general 
anesthesia) 
Less pain (moderate sedation) 
Ablation zone not visible during ablation 
 Higher recurrence rates 
 Higher likelihood of repeat ablation 
Ablation zone visible during ablation 
 Lower recurrence rates 
 Lower likelihood of repeat ablation 
Larger ablation zone per applicator  
(requires fewer applicators) 
Smaller ablation zone per applicator 
(requires more applicators) 
CT monitoring during ablation difficult 
(artifacts) 
CT monitoring during ablation possible 
Interferes with pacemakers No interference with pacemakers 
More likely to damage the collecting system Less likely to damage the collecting system 
(Janzen et al. 2005) 
Less control over individual applicators More control over individual applicators 
Grounding pads (risk of skin burn) Cumbersome equipment 
Table 1. Comparison of main technical features of radiofrequency ablation and cryoablation 
in percutaneous image-guided ablation of renal tumors 
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3.2 Other ablation modalities 
Microwave is a heat-based modality which involves deploying microwave energy (300-3000 
MHz) from a non-tined probe (antenna) into a tumor causing oscillation of ions. This creates 
heat resulting in coagulative necrosis. Advantages include faster ablation times and less 
susceptibility to thermal heat-sink effect (Simon et al., 2005). 
Laser is another heat-based ablation modality that deposits laser energy into the tumor via 
tiny flexible fiber optic conduits. Laser energy raises the tissue temperature and causes 
coagulative necrosis. Laser ablation has been successfully performed in renal tumors (Dick 
et al., 2002), and can be done under CT or MRI guidance. The flexibility of the fiber outside 
of the patient is an advantage when working in a CT or MRI gantry. Relative small ablation 
zones mandate multiple probe placements with laser ablation. 
Irreversible electroporation (IRE) is a non-thermal ablation modality that causes apoptotic 
cell death by creating permanent microscopic pores in cell membranes when cells are 
exposed to specific electrical fields. This modality is much faster than other minimally 
invasive ablation techniques. Another advantage of IRE is that it is not affected by thermal 
sink phenomenon (Rubinsky et al., 2007). Preliminary animal and human experience is 
promising (Deodhar et al., 2011). Due to the stimulation of skeletal muscle by the electric 
field in IRE, the need for general anesthesia with paralytic agents remains a challenge to 
widespread use of the technique. 
High-intensity focused ultrasound (HIFU) is a noninvasive heat-based ablation modality. It 
causes coagulation necrosis by focusing a high-intensity ultrasonic beam onto a small 
volume of target lesion. Respiratory movements and overlying ribs are major problems with 
the use of HIFU in renal tumors (Marberger et al., 2005; Klatte et al., 2009). 
4. Imaging guidance  
Percutaneous image-guided ablation can be performed under ultrasound, computed 
tomography (CT), or magnetic resonance imaging (MRI) guidance. The tumor should be 
well visualized on the imaging modality planned for the procedure. The advantages of 
ultrasound are its "real-time" capability and lack of ionizing radiation. Ultrasound can be 
used for accurate placement of probes before switching to CT or MRI for further monitoring. 
However, imaging with ultrasound is highly operator dependent and may be compromised 
in certain settings, such as patients with a large body habitus, the presence of abundant 
bowel gas, and when the tumor is near a focal loop of bowel that needs to be avoided. 
Another setback to ultrasound is the degradation of landmarks during ablation. In 
cryoablation, image degradation is caused by acoustic shadowing on the far side of the ice 
ball, and in RFA it is produced by micro bubbles. 
CT is the most commonly used imaging modality for guidance (figure 1). It is not as 
operator dependent as ultrasound and is widely accessible to most operators. Its wide field 
of view is excellent to cover the critical organs and structures that need to be avoided. CT 
scanning is much less sensitive to body habitus than is ultrasound and CT images are not 
affected by bowel gas. If CT is chosen as image guidance method, the target lesion should 
ideally be visible on a non-contrast examination. Percutaneous ablation can be performed 
using a conventional CT scanner or a CT scanner with real-time fluoroscopic capability. 
Imaging monitoring with CT during active ablation with RFA is prone to significant artifacts 
due to interference of RF energy with the CT scanner. Cryoablation can be monitored by CT 
imaging during active ablation. 
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Fig. 1. (a) 62-year-old patient with an incidentally discovered left renal cortical mass (arrow). 
Separate session biopsy showed conventional clear cell renal cancer. (b) Cryoablation was 
performed in prone position. This picture is rotated to simulate supine position for ease of 
comparison. The edge of ice ball is clearly visible in renal parenchyma (white arrows). (c) 
Contrast enhanced CT image one day after ablation shows lack of enhancement in the 
ablation zone which covers tumor and an intended margin of renal parenchyma. Follow up 
contrast enhanced CT images at 3 months (d), 15 months (e) and 30 months after ablation (f). 
The tumor and adjacent ablated renal parenchyma continuously get smaller in size. A halo 
at the edge of ablation zone (white arrows) is visible. 
MRI is the least commonly used imaging modality for percutaneous ablation. It provides 
excellent soft tissue resolution with multi planar imaging capability (figure 2). Lack of 
ionizing radiation is a safety advantage of MRI. MR fluoroscopic sequences can be used for 
real-time targeting of tumor. MR thermometry can assess cytotoxic tissue temperatures 
noninvasively. Image-guided percutaneous ablation can be performed using a dedicated 
interventional magnet, a conventional solenoid magnet, or an open magnet. The ice ball is 
visualized as a zone of decreased signal intensity on T1- and T2-weighted images. MRI-
compatible ablation equipment is available to perform both RFA and cryoablation under 
MRI guidance (Boss et al., 2005; Miki et al., 2006).  
a b c 
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Fig. 2. 77-year-old patient with renal cell cancer of the left kidney (arrows). (a) Contrast 
enhanced T1 weighted MR scan demonstrates an enhancing tumor in the lower pole of the 
left kidney. Biopsy confirmed renal cell carcinoma. (b) Two cryoprobes are placed in the 
tumor under T2 weighted MR guidance. (c) During cryoablation, a low signal “ice ball” 
encompasses the lesion. Images c and d are rotated to simulate supine position for ease of 
comparison. (d) Contrast enhanced T1 weighted MRI 3 months after cryoablation 
demonstrates non-enhancement of the tumor and ablation zone, and shrinkage of the 
residual mass. 
5. Indications and patient selection 
Image-guided percutaneous ablations are especially ideal in patients who do not want to 
undergo surgery, elderly patients with significant medical co-morbidities that preclude 
them from surgery, patients with renal insufficiency, solitary kidney, transplanted kidney, 
and multi- focal tumors or patients with diseases such as von Hippel Lindau, which 
a b 
c d 
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predisposes them to develop multiple renal tumors. Documentation of renal cell carcinoma 
by needle biopsy is mandatory, as up to 25% of renal masses smaller than 3 cm are benign 
(American Cancer Society, 2008). Ideally, biopsy should be performed in a session separate 
from ablation. Tumors should be isolated to kidney with no evidence of vascular invasion or 
metastases. The best results are anticipated from tumors smaller than 4 cm in diameter, 
although larger tumors have been successfully ablated. The decision to perform 
percutaneous ablation is best made as a cooperative multidisciplinary agreement between 
an interventional radiologist and a urologist. 
5.1 Pre procedural evaluation  
Before the procedure, a physical exam should be performed, and the patient's medical 
history should be reviewed. Informed consent is required, and patients must understand 
that percutaneous ablations are relatively new procedures. Patients are informed about the 
possibility of retreatment and follow up imaging studies. Allergies to contrast media, 
antibiotic medications, or anesthetic drugs should also be noted. Laboratory blood tests 
should include hematocrit, platelet count, prothrombin time, and international normalized 
ratio (INR), partial thromboplastin time (PTT), and creatinine with calculation of an 
estimated glomerular filtration rate (eGFR). A platelet count of more than 100,000 per mL, 
INR of less than 1.5, and normal PTT would ideally be met prior to the procedure. Patients 
should not be acutely coagulopathic. 
Warfarin, aspirin, and clopidogrel should ideally be stopped at least 7 days before the 
procedure. The operating physician should consult the referring physician prior to 
withholding anticoagulation medication. In patients with strict warfarin requirements, 
special arrangements can be made so that ablation is performed using a "heparin window," 
in which warfarin is held and patients are systemically anticoagulated with heparin until the 
time of procedure. Patients are instructed to abstain from eating for 6 hours prior to ablation 
so they are able to receive intravenous moderate sedation or general anesthesia. They may 
take other routine oral medications with small sips of water. Modification of the insulin 
regimen in diabetics should be considered during the food restriction period prior to the 
procedure. Nephrology consultation may be needed prior to ablation in patients with 
chronic renal insufficiency (estimated GFR less than 60 mL/min). 
6. Ablation procedure 
The patient should be placed in a comfortable position (prone, supine, lateral decubitus, or 
with slight elevation of one side) that also facilitates the procedure. Intravenous midazolam 
and fentanyl are the most commonly used medications for moderate sedation. The drug 
dosage is titrated for patient comfort and is monitored with telemetry and pulse oximetry by 
a sedation nurse or anesthesia team. Alternatively and based on institutional policies, 
percutaneous ablations may be performed under general anesthesia with endotracheal 
intubation. If desired, a biopsy of the lesion can be performed in the same session prior to 
the ablation. A challenge with same day biopsy is that bleeding associated with the biopsy 
may obscure the tumor and potentially affect outcome. 
The procedure plan should be outlined by the operating physician before the procedure. 
The number of probes used for a particular tumor depends on the equipment used and the 
size of tumor. Placement of more than one probe is often required to cover the entire tumor 
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and the desired rim of surrounding parenchyma. The length of devices extending outside of 
the patient and their connecting cords, as well as patient positioning and the angle of probe 
placement, all have major practical implications and should all be planned in advance. 
Frequently, the injection of intravenous contrast medium during the procedure can help 
visualize relatively inconspicuous lesions. Smaller doses of iodinated contrast (50 mL) are 
usually sufficient for CT visualization and can allow for a repeat bolus later in the procedure 
if necessary. Similarly, there are circumstances when sonographic or MRI contrast agents 
may be useful. 
Adjacent critical structures may be damaged when they are located within the target region. 
Occasionally, a second percutaneous needle can be inserted and carbon dioxide, water, air, 
or balloons may be placed to separate bowel, for instance, from the target tumor (Farrell et 
al., 2003; Kam et al., 2004; Gervais et al., 2005b). It is important not to use saline for hydro 
dissection in RFA cases, as saline conducts current and may damage organs. Nonionic 5% 
dextrose in water should be used instead. Certain patient positioning maneuvers or the 
operating physician’s hands may also be used to move away bowel loops from the tumor. 
Retrograde ureteral stents can be used to circulate warm or cold fluid during the ablation 
period to provide some protection to the ureter (Cantwell at al., 2008). The probe can also be 
used as a lever to move the kidney away from adjacent structures (Park & Kim, 2008). If a 
transpleural approach is inevitable, it can be pursued and any pneumothorax that develops 
may be treated accordingly. Alternatively, an iatrogenic pneumothorax or hydrothorax can 
be created to avoid potential damage to the lung. 
Unless a tined RFA probe is used, most probes have no tines and produce an oval zone of 
ablation. After adequate positioning of the probe(s) is complete, the tumor is ablated once or 
more according to the suggested manufacturer protocol. If the patient's renal function 
allows, a contrast-enhanced CT or MRI scan may be performed after removing all probes. 
This will allow for an immediate assessment of the adequacy of the ablation. MRI-guided 
ablations can also be immediately assessed by MR thermometry. Certain areas with 
suboptimal ablation can then be immediately re-treated during the same session. At a 
minimum, it is usually helpful to do a noncontrast scan of the treatment area following 
removal of probes to assess for complications. 
An advantage of cryoablation over heat-based ablation modalities is its relative painlessness 
(Allaf et al., 2005). This may be of importance for patients who cannot undergo general 
anesthesia or receive deep moderate sedation due to medical co morbidities. 
In contrast to heat-based ablation modalities, the ice ball can be clearly seen with CT (Littrup 
et al., 2007; Solomon et al., 2004), MRI (Silverman et al., 2005), and ultrasound imaging (Gill 
et al., 2000). This imaging characteristic allows the operator to ascertain coverage of the 
tumor more confidently and also to better protect certain nearby critical structures. Because 
of this feature, cryo ablated lesions tend to have less residual tumor (Marin et al., 2006). 
Intravenous contrast is not necessarily needed immediately following cryoablation to verify 
proper coverage of tumor by the ablation zone. This is a significant advantage for patients 
with renal insufficiency. The outer edge of the ice ball that is visualized is not cytotoxic. The 
cytotoxic part of an ice-ball is contained a few millimeters inside the visible edge. 
Unlike the heat-based ablation modalities, freezing does not cauterize or coagulate vessels 
within the ablation zone. Hence, patients may be at slightly higher risk of bleeding during 
or immediately following cryoablation. For this reason, patients with borderline coagulation 
status should have laboratory abnormalities more vigorously corrected. One relative 
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limitation of current cryoablation probes is the size of the ablation zone created by a single 
probe as compared with the same size RFA probe. In general, each 2 mm probe creates an 
approximately 2 cm diameter of necrosis (Permpongkosol et al., 2007). For this reason, 
insertion of multiple simultaneous probes is commonly needed to cover the entire tumor 
and desired margin of surrounding parenchyma. A simple rule-of-thumb is to position the 
probes about 1 cm from the margin of the tumor and 1 to 2 cm apart from each other, giving 
priority to the periphery of the tumor (Solomon et al., 2004). It is important to remember 
that all available cryoablation probes currently have an extension cord attached to them. 
This cord contains tubing for gases, and in certain versions, temperature sensor wiring as 
well. The weight of the cord produces torque during and after placement of the probe. 
When planning for cryoablation, it is important to make sure the trajectory of each probe 
has enough purchase inside the patient so they are not constantly pulled or deviated by the 
torque produced by the cord. When positioning the patient for the procedure, it is critical to 
remember to provide enough space between the patient and gantry so that the equipment 
does not contact the gantry during the procedure. Additionally, the operating physician will 
have far more freedom to make fine adjustments during the procedure without having to 
take the patient out of the gantry repeatedly. 
7. Treatment outcomes 
Technical success rates of 97 to 100 percent are reported with RFA and cryoablation (Atwell 
et al., 2008; Boss et al., 2005; Gervais et al., 2005a). In a series of 616 patients, the incidence of 
residual or recurrent tumor was 13.4 percent with a single radiofrequency ablation and 3.9 
percent with a single cryoablation (Gervais et al., 2000). In this series, the overall incidence 
of residual or recurrent tumor after repeated ablation therapy in all patients was 4.2 percent 
(Gervais et al., 2000). The overall 2-year survival rate was 82.5 percent, including patients 
who died of unrelated causes, and the metastasis-free survival rate was 97 percent at 2 years 
(Gervais et al., 2000). Five-year local and distant tumor-free rate after RFA has been reported 
at 94 percent (McDougal et al., 2005). Similar success rates are reported with cryoablation, 
but the mean follow-up time period is shorter at 1 to 2 years (Littrup et al., 2007). 
8. Complications 
The rate of major complications from percutaneous ablation of renal tumors is about 2 to 6 
percent (Atwell et al., 2008; Boss et al., 2005; Johnson at al., 2004). Complications include 
hemorrhage, pneumothorax, and bowel and nerve injury. In contrast to other heat-based 
ablation modalities, cryoablation does not cauterize blood vessels within the ablation zone. 
Therefore, hemorrhage at the ablation zone after removal of probes appears to be slightly 
more common when compared with heat-based ablation modalities. Hemorrhage after 
cryoablation is most often self-limited and responds to conservative management. Damage 
to the renal collecting system and the neighboring structures such as nerves and bowel are 
among other reported complications.  
9. Patient follow up  
If the patient's renal function allows, the ablated tumor should be evaluated by CT or MRI 
without and with intravenous contrast at 1, 3, 6, 12, 18, and 24 months after ablation. Early 
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post ablation studies show the ablation zone as a non-enhancing area surrounded by a thin 
smooth rim of enhancement (Smith & Gillams; 2008). This rim is considered a physiologic 
response to thermal ablation and disappears within 3 months (Merkle et al., 2005). Ideally, 
the ablation zone should include the entire tumor and the expected 5 to 10 mm 
noncancerous rim; (figure 1 c, d; figure 2 d). The ablation zone appears T1 hyper intense and 
T2 hypo intense (Uppot et al., 2009; Kawamoto et al, 2009). The ablation zone continues to 
decrease in size over time (Merkle et al., 2005) (figure 1 d, e, f). Complete disappearance of 
cryoablated tumors over time has been reported (Gill et al., 2005). A thin curvilinear hyper 
attenuating rim or halo on CT imaging, which is hypo intense on T1-weighted images, is 
commonly seen parallel to the tumor extending to the perinephric fat (figure 1 d, e, f). This 
halo may persist for several months after treatment (Uppot et al., 2009; Kawamoto et al, 
2009). Nodular or irregular enhancement within the ablation zone and enlargement of 
ablation zone is considered suspicious for residual tumor or recurrence (Kawamoto et al, 
2009). These areas may be biopsied and if positive for malignancy they can be treated by 
ablation. 
10. Conclusion 
Image-guided percutaneous ablation is a viable option for patients who cannot undergo 
surgery because of medical co morbidities. Experience with these ablation modalities is 
promising. 
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